Chemical Compound Review:
AC1NFJIQ 2-cyano-3-(3,4-dihydroxy-5- nitro-phenyl)-N...
Synonyms:
SureCN34505, AG-A-41658, ACMC-20mm79, CTK0G0511, CTK8E7938, ...
Dingemanse,
Meyerhoff,
Schadrack,
Lautala,
Ethell,
Taskinen,
Burchell,
Piccini,
Brooks,
Korpela,
Pavese,
Karlsson,
Gordin,
Nissinen,
Kaheinen,
Penttilä,
Kaivola,
Lindén,
Müller,
Erdmann,
Muhlack,
Bremen,
Przuntek,
Goetze,
Woitalla,
Tervo,
Nyrönen,
Rönkkö,
Poso,
Sharif,
Ruottinen,
Rinne,
Oikonen,
Bergman,
Haaparanta,
Solin,
Ruotsalainen,
Rinne,
Olanow,
Kieburtz,
Stern,
Watts,
Langston,
Guarnieri,
Hubble,
- Entacapone and motor fluctuations in Parkinson's disease. Riggs, J.E. Ann. Neurol. (1998)
- Entacapone. A review of its use in Parkinson's disease. Holm, K.J., Spencer, C.M. Drugs (1999)
- Entacapone protects from angiotensin II-induced inflammation and renal injury. Helkamaa, T., Finckenberg, P., Louhelainen, M., Merasto, S., Rauhala, P., Lapatto, R., Cheng, Z.J., Reenilä, I., Männistö, P., Müller, D.N., Luft, F.C., Mervaala, E.M. J. Hypertens. (2003)
- The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. Piccini, P., Brooks, D.J., Korpela, K., Pavese, N., Karlsson, M., Gordin, A. J. Neurol. Neurosurg. Psychiatr. (2000)
- In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Smith, K.S., Smith, P.L., Heady, T.N., Trugman, J.M., Harman, W.D., Macdonald, T.L. Chem. Res. Toxicol. (2003)
- Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Smith, L.A., Jackson, M.J., Hansard, M.J., Maratos, E., Jenner, P. Mov. Disord. (2003)
- Entacapone in restless legs syndrome. Sharif, A.A. Mov. Disord. (2002)
- Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression. Männistö, P.T., Lang, A., Rauhala, P., Vasar, E. Eur. J. Pharmacol. (1995)
- Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme. Kurkela, M., García-Horsman, J.A., Luukkanen, L., Mörsky, S., Taskinen, J., Baumann, M., Kostiainen, R., Hirvonen, J., Finel, M. J. Biol. Chem. (2003)
- COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease. Lee, M.S., Kim, H.S., Cho, E.K., Lim, J.H., Rinne, J.O. Neurology (2002)
- Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. Trocóniz, I.F., Naukkarinen, T.H., Ruottinen, H.M., Rinne, U.K., Gordin, A., Karlsson, M.O. Clin. Pharmacol. Ther. (1998)
- Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Illi, A., Sundberg, S., Ojala-Karlsson, P., Scheinin, M., Gordin, A. Clin. Pharmacol. Ther. (1996)
- Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. Smith, L.A., Gordin, A., Jenner, P., Marsden, C.D. Mov. Disord. (1997)
- Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin. Dingemanse, J., Meyerhoff, C., Schadrack, J. British journal of clinical pharmacology. (2002)
- The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease. Heikkinen, H., Nutt, J.G., LeWitt, P.A., Koller, W.C., Gordin, A. Clinical neuropharmacology. (2001)
- Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. Müller, T., Erdmann, C., Muhlack, S., Bremen, D., Przuntek, H., Goetze, O., Woitalla, D. Journal of neural transmission (Vienna, Austria : 1996) (2006)
- Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Kaakkola, S., Teräväinen, H., Ahtila, S., Rita, H., Gordin, A. Neurology (1994)
- The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. Illi, A., Sundberg, S., Ojala-Karlsson, P., Korhonen, P., Scheinin, M., Gordin, A. Clin. Pharmacol. Ther. (1995)
- The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Sawle, G.V., Burn, D.J., Morrish, P.K., Lammertsma, A.A., Snow, B.J., Luthra, S., Osman, S., Brooks, D.J. Neurology (1994)
- Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Lotta, T., Vidgren, J., Tilgmann, C., Ulmanen, I., Melén, K., Julkunen, I., Taskinen, J. Biochemistry (1995)
- The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. Deleu, D., Sarre, S., Ebinger, G., Michotte, Y. J. Pharmacol. Exp. Ther. (1995)
- Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Wikberg, T., Vuorela, A., Ottoila, P., Taskinen, J. Drug Metab. Dispos. (1993)
- Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. Nissinen, E., Kaheinen, P., Penttilä, K.E., Kaivola, J., Lindén, I.B. Eur. J. Pharmacol. (1997)
- COMT inhibitors and liver toxicity. Watkins, P. Neurology (2000)
- Cross talk between the intrarenal dopaminergic and cyclooxygenase-2 systems. Zhang, M.Z., Yao, B., McKanna, J.A., Harris, R.C. Am. J. Physiol. Renal Physiol. (2005)
- A structure-activity relationship study of catechol-O-methyltransferase inhibitors combining molecular docking and 3D QSAR methods. Tervo, A.J., Nyrönen, T.H., Rönkkö, T., Poso, A. J. Comput. Aided Mol. Des. (2003)
- Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction. Ruottinen, H.M., Rinne, J.O., Oikonen, V.J., Bergman, J.R., Haaparanta, M.T., Solin, O.H., Ruotsalainen, U.H., Rinne, U.K. Synapse (1997)
- The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Lautala, P., Ethell, B.T., Taskinen, J., Burchell, B. Drug Metab. Dispos. (2000)
- Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Olanow, C.W., Kieburtz, K., Stern, M., Watts, R., Langston, J.W., Guarnieri, M., Hubble, J. Arch. Neurol. (2004)
- L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Pearce, R.K., Heikkilä, M., Lindén, I.B., Jenner, P. Psychopharmacology (Berl.) (2001)